
    
      The study is an open-label, single-arm, Phase I/II multi-center study to investigate the PK,
      activity and safety of ruxolitinib added to the patient's immunosuppressive regimen in
      infants, children, and adolescents ages ≥28 days to <18 years old with either grade II-IV
      aGvHD or grade II-IV SR-aGvHD. This trial will utilize four age groups: Group 1 includes
      patients ≥12y to <18y, Group 2 includes patients ≥6y to <12y, Group 3 includes patients ≥2y
      to <6y, and Group 4 includes patients ≥28days to <2y.
    
  